
    
      Patients eligible for the study, after signing informed consent will be randomized 1:1 for
      maintenance of renin-angiotensin system inhibitors or switching the antihypertensive therapy
      for other classes according to a pre-specified protocol.

      Patients are going to be followed during hospital stay for evaluation of clinical endpoints.
      Also blood and urine samples will be acquired for evaluation of renin-angiotensin system
      activation.
    
  